泰 達

天津泰達生物醫學工程股份有限公司

Tianjin TEDA Biomedical Engineering Company Limited

(a joint stock company incorporated in the People's Republic of China with limited liability)

（**Stock Code：8189**）

POSITIVE PROFIT ALERT

This announcement is issued by Tianjin TEDA Biomedical Engineering Company Limited (the "Company") and its subsidiaries (collectively the "Group") pursuant to Rule 17.10 of the GEM Listing Rules (the "GEM Listing Rules") of The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (as defined in the GEM Listing Rules).

The board of directors of the Company (the "Board of Directors") (the "Directors") is pleased to inform the shareholders of the Company (the "Shareholders") and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2026 and information currently available to the Board of Directors, the Group is expected to record the following results:

1. revenue ranging from RMB290 million to RMB300 million for the Reporting Period, representing an increase of approximately 28% to 33% as compared to that of RMB226 million for the six months ended June 30, 2025 (the ‘‘CorrespondingPeriod’’); and

2. a net profit attributable to owners of the Company ranging from RMB7 million to RMB10 million for the Reporting Period, representing an increase of approximately 209% to 256% as compared to a net loss attributable to owners of the Company of RMB6 million for the Corresponding Period.

The growth in revenue and net profit attributable to owners of the Company during the Reporting Period is mainly attributable to the rapid expansion of the AI Life Healthcare Business. During the Reporting Period, the AI Life Healthcare Business recorded revenue of approximately RMB100 million to RMB110 million and net profit attributable to owners of the Company of approximately RMB10 million to RMB12 million.

The Board of Directors hereby reminds investors that the Group is still compiling and finalising its interim results for the six months ended 30 June 2026. The information contained in this announcement is solely based on the preliminary review and assessment conducted by the Board of Directors with reference to the unaudited consolidated management accounts of the Group for the six months ended 30 June 2026 and information currently available to the Board of Directors. Such information has not been audited or reviewed by the auditors or the Audit Committee, and may be adjusted upon receipt of further updated information, which may differ from the disclosures set out in this announcement. Further details on the actual financial performance and results of the Group will be disclosed in the interim results announcement for the six months ended 30 June 2026. Pursuant to the GEM Listing Rules, the Group's interim results announcement is expected to be published on 31 August 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the PRC
18 August 2026

As at the date of this announcement, the executive directors of the Company are Ms. Sun Li and Mr. YangZeng; the non-executive directors of the Company are Mr. He Xin, Dr. Li Ximing, Mr. Wang Lei and Mr. Xia Alan Zhe; the independent non-executive directors of the Company are Ms. Gao Chun, Mr. Tu Xiangzhen and Mr. Chen Jiang.